Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Vunakizumab Injection Devices in Healthy Subjects
NCT06182384Phase 1Completed
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Dec 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vunakizumab in plaque psoriasis (2 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Visual Analog Scale for Injection Site Pain at Day 8 and Incidence rate of injection site reaction at Day 8. Started Dec 2023; status: completed.
02
Drugs
vunakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06182384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182384.